Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Share-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Amortization - GoodwillCost of RevenueDepreciation & Amortization (IS)EBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares Issued
Ratios

Legend Biotech (LEGN) Shares Outstanding (2020 - 2024)

Legend Biotech filings provide 5 years of Shares Outstanding readings, the most recent being $367.3 million for Q4 2024.

  • On a quarterly basis, Shares Outstanding rose 0.96% to $367.3 million in Q4 2024 year-over-year; TTM through Dec 2024 was $367.3 million, a 0.96% increase, with the full-year FY2024 number at $367.3 million, up 0.96% from a year prior.
  • Shares Outstanding hit $367.3 million in Q4 2024 for Legend Biotech, up from $363.8 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $367.3 million in Q4 2024 to a low of $266.0 million in Q4 2020.
  • Median Shares Outstanding over the past 5 years was $330.1 million (2022), compared with a mean of $327.1 million.
  • Biggest five-year swings in Shares Outstanding: increased 15.96% in 2021 and later increased 0.96% in 2024.
  • Legend Biotech's Shares Outstanding stood at $266.0 million in 2020, then rose by 15.96% to $308.5 million in 2021, then rose by 7.03% to $330.1 million in 2022, then increased by 10.2% to $363.8 million in 2023, then increased by 0.96% to $367.3 million in 2024.
  • The last three reported values for Shares Outstanding were $367.3 million (Q4 2024), $363.8 million (Q4 2023), and $330.1 million (Q4 2022) per Business Quant data.